It is with great interest, that we read the letter by Lippi and Plebani [1] commenting on our review article recently published in EJIM [2]. To our view both articles converge on the position that serological testing for SARS-CoV-2 is a valuable tool for influencing public health policies, accounting for both general population surveys (post-infection and/or vaccination) and surveys in specialized settings, such as hospitals and nursing homes. We fully agree that the surge of still evolving variants e.g., Omicron variant necessitates the development of updated immunoassays, particularly in cases where Spike or RBD are employed as target antigens, allowing for the accurate detection of emerging variants.
